Dosierung von Antiinfektiva bei Nierenversagen und Nierenersatztherapie in der Intensivmedizin

Empfehlungen der Sektionen Niere der DGIIN, ÖGIAIN und DIVI

Dose adjustment of anti-infective drugs in patients with renal failure and renal replacement therapy in intensive care medicine

Recommendations from the renal section of the DGIIN, ÖGIAIN and DIVI



Viele Antiinfektiva erfordern bei kritisch kranken Patienten mit akuter Nierenschädigung (AKI) und Nierenersatztherapie eine Dosisanpassung, um adäquate therapeutische Konzentrationen zu erreichen.

Ziel der Arbeit

Es sollen grundlegende pharmakokinetische und pharmakodynamische Prinzipien der Dosisanpassung von Arzneimitteln dargestellt und praktische Empfehlungen zur Dosierung von Antiinfektiva auf der Intensivstation geben werden.

Material und Methoden

Die Empfehlungen zur Dosierung von ausgewählten Antiinfektiva wurden basierend auf einer Zusammenschau der Angaben in Fachinformationen, publizierten Studien und Empfehlungen, pharmakokinetischen und pharmakodynamischen Erwägungen sowie Erfahrungen und Expertenmeinungen der Autoren erstellt.


Von 37 Antiinfektiva (31 Antibiotika, 2 Virostatika, 4 Antimykotika) ist bei 8 eine Dosierung unabhängig von der Nierenfunktion möglich. Bei 29 Antiinfektiva war eine konkrete Dosierungsempfehlung für intermittierende Hämodialyse und bei 24 Antiinfektiva für kontinuierliche Hämofiltration möglich.


Anhand aktueller Datenlage werden hier für die wichtigsten Antiinfektiva Empfehlungen zur Dosierung bei Patienten mit AKI und Nierenersatztherapie gegeben.



Many anti-infective drugs require dose adjustments in critically ill patients with acute kidney injury (AKI) and renal replacement therapy, in order to achieve adequate therapeutic drug concentrations.


The fundamental pharmacokinetic and pharmacodynamic principles of drug dose adjustment are presented. Recommendations on anti-infective drug dosage in intensive care are provided.

Materials and methods

We established dose recommendations of selected anti-infective drugs based on information in the summary of product characteristics, published studies and recommendations, pharmacokinetic and pharmacodynamic considerations, and the experience and expert opinion of the authors.


Out of a total of 37 anti-infective drugs (31 antibiotics, 2 antivirals, 4 antifungals) 8 can be administered independent of renal function. For 29 anti-infective drugs, a specific recommendation on drug dosage could be made in case of intermittent hemodialysis and for 24 anti-infective drugs in case of continuous hemo(dia)filtration.


Recommendations on dosing of important anti-infective drugs in critically ill patients with AKI and renal replacement therapy are provided.

This is a preview of subscription content, log in to check access.

Abb. 1
Abb. 2
Abb. 3


  1. 1.

    Ambrose PG, Bhavnani SM, Rubino CM, Louie A, Gumbo T, Forrest A, Drusano GL (2007) Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it’s not just for mice anymore. Clin Infect Dis 44:79–86

    Article  PubMed  CAS  Google Scholar 

  2. 2.

    Bellmann R, Egger P, Gritsch W, Bellmann-Weiler R, Joannidis M, Dunzendorfer S, Wiedermann CJ (2002) Elimination of levofloxacin in critically ill patients with renal failure: influence of continuous veno-venous hemofiltration. Int J Clin Pharmacol Ther 40:142–149

    Article  PubMed  CAS  Google Scholar 

  3. 3.

    Beumier M, Casu GS, Hites M, Seyler L, Cotton F, Vincent JL, Jacobs F, Taccone FS (2014) β‑lactam antibiotic concentrations during continuous renal replacement therapy. Crit Care 18:R105

    Article  PubMed  PubMed Central  Google Scholar 

  4. 4.

    Blot SI, Pea F, Lipman J (2014) The effect of pathophysiology on pharmacokinetics in the critically ill patient—concepts appraised by the example of antimicrobial agents. Adv Drug Deliv Rev 77:3–11

    Article  PubMed  CAS  Google Scholar 

  5. 5.

    Bosso JA, Nappi J, Rudisill C, Wellein M, Bookstaver PB, Swindler J, Mauldin PD (2011) Relationship between vancomycin trough concentrations and nephrotoxicity: a prospective multicenter trial. Antimicrob Agents Chemother 55:5475–5479

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  6. 6.

    Cox ZL, McCoy AB, Matheny ME, Bhave G, Peterson NB, Siew ED, Lewis J, Danciu I, Bian A, Shintani A, Ikizler TA, Neal EB, Peterson JF (2013) Adverse drug events during AKI and its recovery. Clin. J Am Soc Nephrol 8:1070–1078

    Article  CAS  Google Scholar 

  7. 7.

    Czock D, Keller F (2014) Antibiotikadosierung bei Dialysepatienten. Nephrologe 9:477–487

    Article  Google Scholar 

  8. 8.

    Czock D, Keller F, Paar WD, Thalhammer F (2008) Nierenersatztherapie beim kritisch Kranken. Soll man Antibiotika bei kontinuierlicher Hämofiltration anders dosieren? Intensiv- und. Notfallbehandlung, Bd. 33, S 169–183

    Google Scholar 

  9. 9.

    Czock D, Markert C, Hartman B, Keller F (2009) Pharmacokinetics and pharmacodynamics of antimicrobial drugs. Expert Opin Drug Metab. Toxicol, Bd. 5, S 475–487

    Google Scholar 

  10. 10.

    Czock D, Spitaletta M, Keller F (2015) Suboptimal antimicrobial drug exposure in patients with renal impairment. Int J Clin Pharm 37:906–916

    Article  PubMed  CAS  Google Scholar 

  11. 11.

    Dettli L (1976) Drug dosage in renal disease. Clin Pharmacokinet 1:126–134

    Article  PubMed  CAS  Google Scholar 

  12. 12.

    Friedrich JO, Wald R, Bagshaw SM, Burns KE, Adhikari NK (2012) Hemofiltration compared to hemodialysis for acute kidney injury: systematic review and meta-analysis. Crit Care 16:R146

    Article  PubMed  PubMed Central  Google Scholar 

  13. 13.

    Hartmann B, Czock D, Keller F (2010) Drug therapy in patients with chronic renal failure. Dtsch Arztebl Int 107:647–655

    PubMed  PubMed Central  Google Scholar 

  14. 14.

    Heintz BH, Matzke GR, Dager WE (2009) Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. Pharmacotherapy 29:562–577

    Article  PubMed  CAS  Google Scholar 

  15. 15.

    Hoste EA, Bagshaw SM, Bellomo R, Cely CM, Colman R, Cruz DN, Edipidis K, Forni LG, Gomersall CD, Govil D, Honoré PM, Joannes-Boyau O, Joannidis M, Korhonen AM, Lavrentieva A, Mehta RL, Palevsky P, Roessler E, Ronco C, Uchino S, Vazquez JA, Andrade VE, Webb S, Kellum JA (2015) Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Intensive Care Med 41:1411–1423

    Article  PubMed  Google Scholar 

  16. 16.

    Jamal JA, Udy AA, Lipman J, Roberts JA (2014) The impact of variation in renal replacement therapy settings on piperacillin, meropenem, and vancomycin drug clearance in the critically ill: an analysis of published literature and dosing regimens. Crit Care Med 42:1640–1650

    Article  PubMed  Google Scholar 

  17. 17.

    Kalb R, Kram R, Morgera S, Slowinski T, Kindgen-Milles D (2013) Regional citrate anticoagulation for high volume continuous venovenous hemodialysis in surgical patients with high bleeding risk. Ther Apher Dial 17:202–212

    Article  PubMed  CAS  Google Scholar 

  18. 18.

    Kunin CM (1967) A guide to use of antibiotics in patients with renal disease. A table of recommended doses and factors governing serum levels. Ann Intern Med 67:151–158

    Article  PubMed  CAS  Google Scholar 

  19. 19.

    Martinez MN, Papich MG, Drusano GL (2012) Dosing regimen matters: the importance of early intervention and rapid attainment of the pharmacokinetic/pharmacodynamic target. Antimicrob Agents Chemother 56:2795–2805

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  20. 20.

    Matzke GR, Aronoff GR, Atkinson AJ Jr, Bennett WM, Decker BS, Eckardt KU, Golper T, Grabe DW, Kasiske B, Keller F, Kielstein JT, Mehta R, Mueller BA, Pasko DA, Schaefer F, Sica DA, Inker LA, Umans JG, Murray P (2011) Drug dosing consideration in patients with acute and chronic kidney disease—a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 80:1122–1137

    Article  PubMed  CAS  Google Scholar 

  21. 21.

    MIC- and Inhibition zone diameter distributions of microorganisms without and with resistance mechanisms. Zugegriffen: 05. März 2018

  22. 22.

    Norton K, Ingram PR, Heath CH, Manning L (2014) Risk factors for nephrotoxicity in patients receiving outpatient continuous infusions of vancomycin in an Australian tertiary hospital. J Antimicrob Chemother 69:805–808

    Article  PubMed  CAS  Google Scholar 

  23. 23.

    Palevsky PM, Zhang JH, O’Connor TZ, Chertow GM, Crowley ST, Choudhury D, Finkel K, Kellum JA, Paganini E, Schein RM, Smith MW, Swanson KM, Thompson BT, Vijayan A, Watnick S, Star RA, Peduzzi P (2008) Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med 359:7–20

    Article  PubMed  CAS  Google Scholar 

  24. 24.

    Pea F, Viale P, Furlanut M (2005) Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet 44:1009–1034

    Article  PubMed  CAS  Google Scholar 

  25. 25.

    Seyler L, Cotton F, Taccone FS, De Backer D, Macours P, Vincent JL, Jacobs F (2011) Recommended β‑lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy. Crit Care 15:R137

    Article  PubMed  PubMed Central  Google Scholar 

  26. 26.

    Tian Q, Gomersall CD, Ip M, Tan PE, Joynt GM, Choi GY (2008) Adsorption of amikacin, a significant mechanism of elimination by hemofiltration. Antimicrob Agents Chemother 52:1009–1013

    Article  PubMed  CAS  Google Scholar 

  27. 27.

    Udy AA, Baptista JP, Lim NL, Joynt GM, Jarrett P, Wockner L, Boots RJ, Lipman J (2014) Augmented renal clearance in the ICU: results of a multicenter observational study of renal function in critically ill patients with normal plasma creatinine concentrations. Crit Care Med 42:520–527

    Article  PubMed  CAS  Google Scholar 

  28. 28.

    Vandecasteele SJ, De Vriese AS, Tacconelli E (2013) The pharmacokinetics and pharmacodynamics of vancomycin in clinical practice: evidence and uncertainties. J Antimicrob Chemother 68:743–748

    Article  PubMed  CAS  Google Scholar 

  29. 29.

    Varma MV, Feng B, Obach RS, Troutman MD, Chupka J, Miller HR, El-Kattan A (2009) Physicochemical determinants of human renal clearance. J Med Chem 52:4844–4852

    Article  PubMed  CAS  Google Scholar 

  30. 30.

    Vilay AM, Churchwell MD, Mueller BA (2008) Clinical review: Drug metabolism and nonrenal clearance in acute kidney injury. Crit Care 12:235

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Prof.(apl.) Dr. D. Czock.

Ethics declarations


D. Czock, D. Kindgen-Milles, S. John, M. Schmitz, A. Jörres, M. Oppert, und C. Willam geben an, dass kein Interessenkonflikt besteht. M. Joannidis erhielt Vortrags‑/Konsulentenhonorare von den Firmen Baxter Healthcare Corp, CSL Behring, Fresenius und Astute Medical sowie Forschungsunterstützung von der Firma Fresenius. J. T. Kielstein erhielt Vortragshonorare von den Firmen Fresenius Medical Care, Baxter und Terumo BCT sowie Forschungsunterstützung von der Firma ExThera Medical. V. Schwenger erhielt Vortragshonorare von den Firmen Fresenius Medical Care und Baxter. A. Zarbock erhielt finanzielle Unterstützung von den Firmen Astute Medical und Fresenius.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Additional information


M. Joannidis, Innsbruck

S. John, Nürnberg

Caption Electronic Supplementary Material

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Czock, D., Schwenger, V., Kindgen-Milles, D. et al. Dosierung von Antiinfektiva bei Nierenversagen und Nierenersatztherapie in der Intensivmedizin. Med Klin Intensivmed Notfmed 113, 384–392 (2018).

Download citation


  • Akutes Nierenversagen
  • Nierenersatztherapie
  • Antibiotika
  • Pharmakodynamik
  • Pharmakokinetik


  • Acute kidney injury
  • Renal replacement therapy
  • Antibiotics
  • Pharmacodynamics
  • Pharmacokinetics